| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniel M Togasaki, Peter Protell, Louis C S Tan, J William Langston, Donato A Di Monte, Maryka Qui. Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology. vol 48. issue 3. 2005-05-24. PMID:15721172. |
these results show that impairing buffering by preventing dopamine reuptake can induce dyskinesias and can also augment levodopa-induced dyskinesias. |
2005-05-24 |
2023-08-12 |
monkey |
| Daniel M Togasaki, Peter Protell, Louis C S Tan, J William Langston, Donato A Di Monte, Maryka Qui. Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology. vol 48. issue 3. 2005-05-24. PMID:15721172. |
thus, this study suggests that diminished buffering capacity for dopamine could play a role in the development of dyskinesias, and that an endogenous mechanism might exist that ameliorates dyskinesias. |
2005-05-24 |
2023-08-12 |
monkey |
| Francesco Bibbiani, Lauren C Costantini, Raj Patel, Thomas N Chas. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Experimental neurology. vol 192. issue 1. 2005-04-14. PMID:15698620. |
levodopa or short-acting dopamine (da) agonist treatment of advanced parkinsonian patients exposes striatal da receptors to non-physiologic intermittent stimulation that contributes to the development of dyskinesias and other motor complications. |
2005-04-14 |
2023-08-12 |
monkey |
| M Morelli, J Warda. Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotoxicity research. vol 3. issue 6. 2005-04-12. PMID:15111244. |
the most effective treatment of parkinson's disease (pd) is, at present, the dopamine precursor l-3,4-dihydroxyphenylalanine (l-dopa), however a number of disadvantages such as a loss of drug efficacy and severe side-effects (psychoses, dyskinesias and on-off phenomena) limit long-term effective utilisation of this drug. |
2005-04-12 |
2023-08-12 |
rat |
| Timothy Brown, Carmen de Groote, Jonathan Brotchi. Recent advances in the treatment of L-DOPA-induced dyskinesia. IDrugs : the investigational drugs journal. vol 5. issue 5. 2005-03-28. PMID:15570465. |
the most widely used treatment for pd is administration of the dopamine precursor l-dopa, although this eventually results in uncontrolled involuntary movements (dyskinesia) that can be more debilitating than the underlying disease itself. |
2005-03-28 |
2023-08-12 |
Not clear |
| Timothy Brown, Carmen de Groote, Jonathan Brotchi. Recent advances in the treatment of L-DOPA-induced dyskinesia. IDrugs : the investigational drugs journal. vol 5. issue 5. 2005-03-28. PMID:15570465. |
the causes of l-dopa-induced dyskinesia are unclear, but probably involve non-physiological pulsatile stimulation of dopamine receptors or non-physiological dopamine release (eg, from serotonergic nerve terminals) in the striatum. |
2005-03-28 |
2023-08-12 |
Not clear |
| Thomas Carlsson, Christian Winkler, Corinna Burger, Nicholas Muzyczka, Ronald J Mandel, Angela Cenci, Anders Björklund, Deniz Kiri. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain : a journal of neurology. vol 128. issue Pt 3. 2005-03-28. PMID:15659429. |
in this study we used 33 rats with severe nigrostriatal dopamine depletion and showed that in vivo gene transfer of the da-synthetic enzymes tyrosine hydroxylase (th) and gtp cyclohydrolase 1 (gch1) using recombinant adeno-associated virus vectors can provide a constant source of dopa production locally in the striatum, at a level that is effective in reducing l-dopa-induced dyskinesias by >85%, and reverse lesion-induced motor impairments. |
2005-03-28 |
2023-08-12 |
rat |
| Naila Ismayilova, Alan Crossman, Alexei Verkhratsky, Jonathan Brotchi. Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats. European journal of pharmacology. vol 497. issue 2. 2005-03-15. PMID:15306204. |
the pathophysiology of parkinson's disease and l-3,4-dihydroxyphenylalanine (l-dopa)-induced dyskinesia are characterised by an imbalance between activity of the direct and indirect pathways regulated by dopamine d1 and d2 receptors, respectively. |
2005-03-15 |
2023-08-12 |
rat |
| Incarnation Aubert, Céline Guigoni, Kerstin Håkansson, Qin Li, Sandra Dovero, Nicole Barthe, Bernard H Bioulac, Christian E Gross, Gilberto Fisone, Bertrand Bloch, Erwan Bezar. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Annals of neurology. vol 57. issue 1. 2005-03-14. PMID:15514976. |
our data suggest that levodopa-induced dyskinesia results from increased dopamine d(1) receptor-mediated transmission at the level of the direct pathway. |
2005-03-14 |
2023-08-12 |
monkey |
| Apomorphine (Apokyn) for advanced Parkinson's Disease. The Medical letter on drugs and therapeutics. vol 47. issue 1200. 2005-02-09. PMID:15647705. |
like other dopamine agonists it can cause nausea and vomiting, orthostatic hypotension, drowsiness, "sleep attacks" and dyskinesias. |
2005-02-09 |
2023-08-12 |
Not clear |
| Raúl de la Fuente-Fernández, Vesna Sossi, Zhigao Huang, Sarah Furtado, Jian-Qiang Lu, Donald B Calne, Thomas J Ruth, A Jon Stoess. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain : a journal of neurology. vol 127. issue Pt 12. 2005-01-19. PMID:15329355. |
levodopa-induced changes in synaptic dopamine levels increase with progression of parkinson's disease: implications for dyskinesias. |
2005-01-19 |
2023-08-12 |
Not clear |
| Raúl de la Fuente-Fernández, Vesna Sossi, Zhigao Huang, Sarah Furtado, Jian-Qiang Lu, Donald B Calne, Thomas J Ruth, A Jon Stoess. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain : a journal of neurology. vol 127. issue Pt 12. 2005-01-19. PMID:15329355. |
we investigated by pet with [11c]raclopride whether parkinson's disease progression modifies the striatal changes in synaptic dopamine levels induced by levodopa administration, and whether this modification, if present, could have an impact on the emergence of dyskinesias. |
2005-01-19 |
2023-08-12 |
Not clear |
| Raúl de la Fuente-Fernández, Vesna Sossi, Zhigao Huang, Sarah Furtado, Jian-Qiang Lu, Donald B Calne, Thomas J Ruth, A Jon Stoess. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain : a journal of neurology. vol 127. issue Pt 12. 2005-01-19. PMID:15329355. |
patients with peak-dose dyskinesias had larger 1-h increases in synaptic dopamine levels than stable responders, but there were no between-group differences in [11c]raclopride binding 4 h post-levodopa. |
2005-01-19 |
2023-08-12 |
Not clear |
| Raúl de la Fuente-Fernández, Vesna Sossi, Zhigao Huang, Sarah Furtado, Jian-Qiang Lu, Donald B Calne, Thomas J Ruth, A Jon Stoess. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain : a journal of neurology. vol 127. issue Pt 12. 2005-01-19. PMID:15329355. |
large levodopa-induced increases in synaptic dopamine concentration can lead to dramatic changes in receptor occupancy, which may be responsible for the emergence of peak-dose dyskinesias in parkinson's disease. |
2005-01-19 |
2023-08-12 |
Not clear |
| J Donaldson, F S LaBella, D Gesse. Enhanced autoxidation of dopamine as a possible basis of manganese neurotoxicity. Neurotoxicology. vol 2. issue 1. 2005-01-19. PMID:15622724. |
manganese, by enhancing the oxidation of dopamine, may augment considerably the production of neurotoxins emanating from this process and, under in vivo conditions, could be expected to contribute significantly to the neurodegenerative changes that accompany manganese dyskinesia in man. |
2005-01-19 |
2023-08-12 |
Not clear |
| Kerstin Håkansson, Maria Lindskog, Laura Pozzi, Alessandro Usiello, Gilberto Fison. DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia. Parkinsonism & related disorders. vol 10. issue 5. 2004-09-14. PMID:15196506. |
the involvement of darpp-32 in dopamine and adenosine transmission and the possible role played by abnormal regulation of darpp-32 phosphorylation in levodopa-induced dyskinesia are discussed. |
2004-09-14 |
2023-08-12 |
Not clear |
| Pierre J Blanchet, Frédéric Calon, Marc Morissette, Abdallah Hadj Tahar, Nancy Bélanger, Pershia Samadi, Richard Grondin, Laurent Grégoire, Leonard Meltzer, Thérèse Di Paolo, Paul J Bédar. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism & related disorders. vol 10. issue 5. 2004-09-14. PMID:15196509. |
studies indicate that sustained dopamine d2 receptor occupancy can prevent and reverse existing dyskinesias. |
2004-09-14 |
2023-08-12 |
Not clear |
| Matthew J Hansard, Lance A Smith, Michael J Jackson, Sharon C Cheetham, Peter Jenne. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates. Movement disorders : official journal of the Movement Disorder Society. vol 19. issue 1. 2004-08-31. PMID:14743355. |
long-term treatment of parkinson's disease (pd) with levodopa (l-dopa) induces dyskinesia that, once established, is provoked by each dose of l-dopa or a dopamine (da) agonist. |
2004-08-31 |
2023-08-12 |
Not clear |
| Melanie Hamann, Angelika Richte. Striatal increase of extracellular dopamine levels during dystonic episodes in a genetic model of paroxysmal dyskinesia. Neurobiology of disease. vol 16. issue 1. 2004-08-18. PMID:15207264. |
striatal increase of extracellular dopamine levels during dystonic episodes in a genetic model of paroxysmal dyskinesia. |
2004-08-18 |
2023-08-12 |
Not clear |
| Olivier Guillin, Nathalie Griffon, Erwan Bezard, Ludovic Leriche, Jorge Diaz, Christian Gross, Pierre Sokolof. Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease. European journal of pharmacology. vol 480. issue 1-3. 2004-07-22. PMID:14623353. |
these results suggest that the dopamine d3 receptor participates in both dyskinesia and the therapeutic action of levodopa and that partial agonists may normalize dopamine d3 receptor function and correct side-effects of levodopa therapy in pd patients. |
2004-07-22 |
2023-08-12 |
rat |